SEC Form 4 · accession 0001127602-17-033980
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregg H Alton
Officer — EVP Comm&Acs ALA, Corp&Med Aff
Period of report
Dec 1, 2017
Accepted (ET)
Dec 5, 2017 · 6:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 1, 2017 | M | 8,625 | $24.905 | A | 70,988 | D | |
| Common StockF2 | Dec 1, 2017 | S | 11,400 | $74.4593 | D | 59,588 | D | |
| Common StockF3 | Dec 1, 2017 | S | 3,600 | $75.1988 | D | 55,988 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F4 | $24.905 | Dec 1, 2017 | M | 8,625 | D | — | Jul 29, 2019 | Common Stock | 8,625 | 16,126 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2Sale prices reported for the transaction reported here range from $73.86 to $74.82. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request
- F3Sale prices reported for the transaction reported here range from $74.88 to $75.57. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request.
- F4The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.